At low viscosity (1 cP), this reduction in injection time was modest, around 25% (data not shown)
Many employers recognized that these drugs could have beneficial health impacts for their workforce, although they disagreed about the extent to which these drugs would reduce other healthcare use or provide a return on their investment
Maggie Aime, MSN, RN Author Maggie Aime is a registered nurse with over 25 years of healthcare experience, who brings medical topics to life through informative and inspiring content
While sommarutide is undoubtedly an exciting potential treatment option, there is still a lack of clear clinical data on the mechanism of action of GLP-1 agonists in NASH, such as whether GLP-1 agonists have a direct, independent role in improving NASH, or simply by improving body weight, insulin resistance, and so on
These outcomes not only improve patient health and quality of life but also increase physician confidence in prescribing GLP-1 therapies
In the main 80-week trial, the top dose produced an average of 28.3% among those who stayed on treatment, and 25.0% for everyone who started
